| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITCI | Common Stock | Award | $0 | +30,847 | +2.9% | $0.000000 | 1,101,176 | 31 Jan 2025 | Direct | F1 |
| transaction | ITCI | Common Stock | Tax liability | $1,934,591 | -15,233 | -1.4% | $127.00 | 1,085,943 | 31 Jan 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITCI | Restricted Stock Units | Award | $0 | +121,212 | $0.000000 | 121,212 | 03 Feb 2025 | Common Stock | 121,212 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | On March 10, 2022, the reporting person was granted performance-based restricted stock units ("PRSUs") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 30,847 PRSUs were vested upon achievement of the reporting person's performance criteria. |
| F2 | Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person. |
| F3 | Each restricted stock unit represents a contingent right to receive one share of common stock. |
| F4 | On February 3, 2025, the reporting person was granted 121,212 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. |